Melina Rapoport
Melina Rapoport has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Petroni
Servicio Antimicrobianos, Departamento de Bacteriología, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina
3 shared publications - Fernando Pasteran
Laboratorio Nacional/Regional de Referencia en Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires 1281, Argentina
3 shared publications - Alejandra Corso
Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistance (NRLAR), National Institute of Infectious Diseases (INEI), ANLIS “Dr. Carlos G. Malbrán” , Buenos Aires
2 shared publications - Diego Faccone
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires 1425, Argentina
2 shared publications Ezequiel Albornoz
Servicio Antimicrobianos, Departamento de Bacteriología, Instituto Nacional de Enfermedades Infecciosas-ANLIS 'Dr Carlos G. Malbrán', Av. Vélez Sarsfield 563 (C1282AFF), Ciudad Autónoma de Buenos Aires, Argentina
2 shared publicationsLeonor Guerriero
Servicio Antimicrobianos, Departamento de Bacteriología, Instituto Nacional de Enfermedades Infecciosas-ANLIS 'Dr Carlos G. Malbrán', Av. Vélez Sarsfield 563 (C1282AFF), Ciudad Autónoma de Buenos Aires, Argentina
2 shared publications
Latest Publications
- 1 December 2014
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 2 (4) , 322-326
Analysis of plasmid-mediated quinolone resistance genes in clinical isolates of the tribe Proteeae from Argentina: First report of qnrD in the Americas
- 1 December 2014
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 2 (4) , 322-326
Analysis of plasmid-mediated quinolone resistance genes in clinical isolates of the tribe Proteeae from Argentina: First report of qnrD in the Americas
- Open Access
- 17 February 2012
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 6 (05) , 452-456
Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
Introduction: Tigecycline and intravenous (i.v.) fosfomycin could be alternative therapeutic options for the treatment of carbapenemase-possessing Enterobacteriaceae bacterial infections. However, routine laboratories are forced to test these drugs using minimum inhibitory concentration (MIC) methods as zone breakpoints are not available for the disc diffusion technique. Methodology: Clinical and Laboratory Standards Institute methods for agar dilution and disc diffusion were compared to determine tentative zone breakpoints that best correlate to tigecycline and i.v. fosfomycin MIC breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing. A total of 195 Enterobacteriaceae with defined mechanisms of resistance were tested in duplicate assays. Half of the strains were characterized as carbapenemase producers (KPC-2, OXA-48, OXA-163, VIM-1, VIM-2, IMP-8, NDM-1). Results: Corresponding zone diameters of susceptible ≥15mm, resistant ≤12mm and susceptible ≥17mm, resistant ≤15mm for the 50µg fosfomycin plus 50µg glucose-6-phosphate and 200µg fosfomycin plus 50µg glucose-6-phosphate discs, respectively, allowed categorization of the strains with an acceptable level of error (< 10% minor errors, < 1.5 % major errors, < 1% very major errors and categorical agreement > 90%). For the 15µg tigecycline disc, the best performance was achieved with the corresponding zone diameters of susceptible ≥ 21mm and resistant ≤ 16mm, which eliminated the very major and major errors but not the minor errors (34.4%). Conclusions: Based on these results, tigecycline and fosfomycin can be included in the routine panel of antibiotics for susceptibility testing by disc diffusion to provide fast and reliable information for the selection of treatment alternatives, especially for strains with extreme resistance, as carbapenemase producers.
- 17 February 2012
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 6 (05) , 452-456
Open AccessTigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae
Introduction: Tigecycline and intravenous (i.v.) fosfomycin could be alternative therapeutic options for the treatment of carbapenemase-possessing Enterobacteriaceae bacterial infections. However, routine laboratories are forced to test these drugs using minimum inhibitory concentration (MIC) methods as zone breakpoints are not available for the disc diffusion technique. Methodology: Clinical and Laboratory Standards Institute methods for agar dilution and disc diffusion were compared to determine tentative zone breakpoints that best correlate to tigecycline and i.v. fosfomycin MIC breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing. A total of 195 Enterobacteriaceae with defined mechanisms of resistance were tested in duplicate assays. Half of the strains were characterized as carbapenemase producers (KPC-2, OXA-48, OXA-163, VIM-1, VIM-2, IMP-8, NDM-1). Results: Corresponding zone diameters of susceptible ≥15mm, resistant ≤12mm and susceptible ≥17mm, resistant ≤15mm for the 50µg fosfomycin plus 50µg glucose-6-phosphate and 200µg fosfomycin plus 50µg glucose-6-phosphate discs, respectively, allowed categorization of the strains with an acceptable level of error (< 10% minor errors, < 1.5 % major errors, < 1% very major errors and categorical agreement > 90%). For the 15µg tigecycline disc, the best performance was achieved with the corresponding zone diameters of susceptible ≥ 21mm and resistant ≤ 16mm, which eliminated the very major and major errors but not the minor errors (34.4%). Conclusions: Based on these results, tigecycline and fosfomycin can be included in the routine panel of antibiotics for susceptibility testing by disc diffusion to provide fast and reliable information for the selection of treatment alternatives, especially for strains with extreme resistance, as carbapenemase producers.
- 1 January 2011
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 69 (1) , 94-97
Emergence of Metallo-β-lactamases in Enterobacteriaceaefrom Argentina
- 1 January 2011
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 69 (1) , 94-97
Emergence of Metallo-β-lactamases in Enterobacteriaceaefrom Argentina
- Open Access
- 1 January 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (1) , 474-475
Novel Variant ( bla VIM-11 ) of the Metallo-β-Lactamase bla VIM Family in a GES-1 Extended-Spectrum-β-Lactamase-Producing Pseudomonas aeruginosa Clinical Isolate in Argentina
- 1 January 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (1) , 474-475
Open AccessNovel Variant ( bla VIM-11 ) of the Metallo-β-Lactamase bla VIM Family in a GES-1 Extended-Spectrum-β-Lactamase-Producing Pseudomonas aeruginosa Clinical Isolate in Argentina